Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Accumulated Expenses (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Accumulated Expenses for 14 consecutive years, with $993000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 7.93% to $993000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $993000.0 through Dec 2025, up 7.93% year-over-year, with the annual reading at $993000.0 for FY2025, 7.93% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $993000.0 at Plus Therapeutics, up from $920000.0 in the prior quarter.
  • The five-year high for Accumulated Expenses was $993000.0 in Q4 2025, with the low at $920000.0 in Q4 2024.
  • Average Accumulated Expenses over 4 years is $972250.0, with a median of $988000.0 recorded in 2022.
  • The sharpest move saw Accumulated Expenses dropped 6.79% in 2024, then rose 7.93% in 2025.
  • Over 4 years, Accumulated Expenses stood at $989000.0 in 2022, then decreased by 0.2% to $987000.0 in 2023, then decreased by 6.79% to $920000.0 in 2024, then increased by 7.93% to $993000.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $993000.0, $920000.0, and $987000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.